Lyra Therapeutics terminates Waltham sublease; pays $2.1M termination fee

Lyra Therapeutics, Inc.

Termination of sublease for 23,704 sq ft at 880 Winter Street, Waltham, MA, effective March 31, 2026.
Company pays $2,100,000 termination payment; rent obligations ceased January 31, 2026.
Upon surrender and payment, RVAC Medicines will release $600,501 letter of credit security deposit.
Sublease originally dated December 21, 2023; premises must be surrendered by May 31, 2026.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Lyra Therapeutics, Inc. terminated 880 Winter Street Sublease with RVAC Medicines (US), Inc. valued at termination payment of $2,100,000.00 (effective 2026-04-13).

Action: termination
Agreement: lease
Counterparty: RVAC Medicines (US), Inc.
Value: termination payment of $2,100,000.00
Effective: 2026-04-13

Exact text from the filing

On April 13, 2026, Lyra Therapeutics, Inc. (the “Company”) entered into a Termination of Sublease with RVAC Medicines (US), Inc. to terminate the Company’s sublease for approximately 23,704 rentable square feet at 880 Winter Street, Waltham, Massachusetts.

View on SEC.gov

119 material agreements filed in the last 30 days. Browse all material agreements →

Lyra Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-160421

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.